Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Operations (2019 - 2025)

C4 Therapeutics' Cash from Operations history spans 7 years, with the latest figure at 22145000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 23.49% year-over-year to 22145000.0; the TTM value through Dec 2025 reached 98694000.0, down 51.47%, while the annual FY2025 figure was 98694000.0, 51.47% down from the prior year.
  • Cash from Operations reached 22145000.0 in Q4 2025 per CCCC's latest filing, up from 31207000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4974000.0 in Q2 2024 to a low of 33285000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 23179650.0, with a median of 24071000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: surged 73.82% in 2024, then crashed 142.4% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 25671000.0 in 2021, then fell by 13.47% to 29128000.0 in 2022, then rose by 17.57% to 24009000.0 in 2023, then rose by 25.31% to 17932000.0 in 2024, then dropped by 23.49% to 22145000.0 in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Cash from Operations are 22145000.0 (Q4 2025), 31207000.0 (Q3 2025), and 12057000.0 (Q2 2025).